Overview

MTD, Safety and Efficacy of NYH817G and NYH100P in Monotherapy and Combination in Patients With Advanced Solid Tumors

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The objectives of this study are: Part 1: - To assess the MTD, safety and efficacy of each NYH817G and NYH100P in monotherapy in patients with advanced solid tumors who have failed approved standard therapies. - To assess the PK properties and the preliminary effectiveness of monotherapy of NYH817G and NYH100P. Part 2: - To assess the MTD, RP2D, safety and efficacy of NYH817G and NYH100P in combination therapy in patients with advanced solid tumors who have failed approved standard therapies - To assess the PK properties, the preliminary effectiveness and the changes in metabolism of combination therapy of NYH817G and NYH100P.
Phase:
Phase 1
Details
Lead Sponsor:
Haim Bio Co., Ltd.